Energy balance
Metformin therapy (2000 mg/day for 48 weeks) improves liver histology and serum ALT levels in approximately 30% of patients with NASH, primarily through weight loss rather than direct insulin sensitization.
For NASH patients, metformin (up to 2g/day) can improve liver health, but only about 3 in 10 people see significant histological benefits. Crucially, this benefit appears driven by the weight loss the drug causes, not its direct effect on insulin. If you do not lose weight on metformin, you are unlikely to see liver histology improvements. Gastrointestinal side effects are common but often manageable with slow dose titration.
Metformin leads to improvements in liver histology and ALT levels in 30% of patients with NASH, probably by its effects in causing weight loss.
Why this rating
Pilot study, open-label, small sample size (n=26), no control group, but rigorous histological assessment.
Source
Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis
Rohit Loomba et al. · Alimentary Pharmacology & Therapeutics · 2008
DOI 10.1111/j.1365-2036.2008.03869.x
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →